SAN JOSE, Calif. and LAS VEGAS, Nov. 14, 2022 (GLOBE NEWSWIRE) — BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, today at HLTH 2022 announced an enterprise agreement with CSL Behring, a leading biotechnology company. Following the swift and successful launch of CSL Behring’s Hizentra® app, BrightInsight will help CSL Behring build, launch, and maintain digital solutions for its late stage and marketed rare disease therapies. The expanded partnership includes plans for additional apps and geographic expansion. BrightInsight will also serve as legal manufacturer of record (LMR).

Read more here.